sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3;

and Q_1 is an electronegative leaving group.

28. (Amended) A pharmaceutical composition comprising a physiologically acceptable carrier and a compound of the formula:

$$Z\text{-}Q_2\text{-}Asp\text{-}Q_1$$

where Z is an N-terminal protecting group;

Q_2 is 0 to 4 amino acids such that Q_2-Asp substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3;

and

Q_1 is an electronegative leaving group.

43. (Amended) A method of treating inflammation or treating an autoimmune disease in a mammal in need of such treatment comprising administering to said mammal an effective amount of a compound of the formula:

$$Z\text{-}Q_2\text{-}Asp\text{-}Q_1$$

where Z is an N-terminal protecting group;

Q_2 is 0 to 4 amino acids such that the sequence Q_2-Asp substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3; and

Q_1 is an electronegative leaving group.